Illumina Ventures, a San Francisco, CA-based healthcare-focused venture firm, closed its second investment fund, at $325m.
The latest fund is anchored by Illumina, Inc. (Nasdaq: ILMN), with the majority of the total committed capital from other strategic and financial investors, including the Ireland Strategic Investment Fund (ISIF).
Led by Nick Naclerio, Founding Partner, Illumina Ventures is an independently managed, healthcare-focused venture firm which support entrepreneurs in advancing science and technologies into market-leading companies to transform healthcare. The firm focuses on investment in:
- life science tools,
- therapeutics,
- diagnostics, and
- personal wellness.
Since its launch in 2016, Illumina Ventures has made investments in 25 companies, including Actym Therapeutics, Alamar Biosciences, Biota Technology, Cernostics, Cradle Genomics, Delfi Diagnostics, DNA Script, Encoded Therapeutics, Genome Medical, Kallyope, LetsGetChecked, Luna DNA, NanoCellect, Pattern Bioscience, Rebus Biosystems, Ribometrix, Serimmune, SQZ Biotech (NYSE: SQZ), Stilla Technologies, Twist Bioscience (Nasdaq: TWST) and Walking Fish Therapeutics.
The latest fund brought its total capital under management to $560m.
FinSMEs
20/09/2021